Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIDOL: Ziconotide for Refractory Neuropathic Pain in Spinal Cord Injury
NCT03942848Phase 3Unknown
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Modified Peptides, Native Peptides
01
Overview
A Phase 3 trial of ziconotide in neuropathic pain, sponsored by Hospices Civils de Lyon. Status: unknown.
02
Drugs
ziconotide
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT03942848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942848.